Partial nephrectomy (PN) may help prevent renal insufficiency, hypertension, and other unfavorable health outcomes in older people with nonmetastatic T1a renal cell carcinoma (RCC), according to a study involving >4,500 individuals. Participants were ≥75 years of age with surgically-treated nonmetastatic T1a RCC. Investigators looked at the impact partial vs radical nephrectomy had on other-cause, cancer-specific, and 30-day mortality. Among the results:
- 42% of patients had partial nephrectomy.
- Those undergoing partial nephrectomy were 33% less likely than those who had radical nephrectomy to experience other-cause mortality.
- The favorable outcome was seen across all ages evaluated.
- Those in the partial nephrectomy group were 36% less likely to experience cancer-specific mortality.
- 30-day mortality rates did not differ.
Marchioni M, Preisser F, Bandini M, et al. Comparison of partial versus radical nephrectomy effect on other-cause mortality, cancer-specific mortality, and 30-day mortality in patients older than 75 years. [Published online ahead of print February 2, 2018]. Eur Urol Focus. doi:10.1016/j.euf.2018.01.007
This Week's Must Reads
Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.
Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.
Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.
Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.
Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.
Must Reads in Renal Cell Carcinoma
Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4
Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010
RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021
Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001
One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617